Long-Term Renoprotection of Optimal Antiproteinuric Doses of Benazepril and Losartan in Chronic Renal Insufficiency
Status:
Terminated
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The primary goal of the trial was to evaluate whether the optimal antiproteinuric doses of
benazepril (an ACE inhibitor) or losartan (an ARB), as compared with their conventional
doses, can safely improve the long-term renal outcome in nondiabetic patients with
proteinuria and chronic renal insufficiency. The second aim was to compare the long-term
renal protection between benazepril and losartan at similar clinical setting.